KM Research Hub
← 返回论文库
部分完成 入排:符合 图源:可得 入排置信度 0.98

Serplulimab Plus Chemotherapy, with or without HLX04, versus Chemotherapy as First-Line Treatment for Nonsquamous NSCLC: Final Survival Analysis of the Phase III ASTRUM-002 Study.

Xuezhi Hao, Lin Wang, Yanrong Hao, Yanping Hu, Chun Chen, Bi Chen, Yunchao Huang, Aimin Zang, Yan Wang, Zhendong Chen, Wu Zhuang, Jinsheng Shi, Xiubao Ren, Ligong Nie, Guohua Yu, Feng Luo, Yimin Mao, Xiang Wang, Baolan Li, Yuansong Bai, Jianhua Shi, Hongyan Ni, Xiaoli Hou, Haoyu Yu, Jing Li, Qingyu Wang, Jun Zhu, Yuankai Shi, ASTRUM-002 Study Group

Cancer Commun (Lond) 46 0034

PMID42282892
PMCIDPMC13250280
DOI10.34133/cancomm.0034
发表日期2026-06-12
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

Background: ASTRUM-002 met the primary endpoint of progression-free survival (PFS) with the combination of serplulimab plus HLX04 (bevacizumab biosimilar) and chemotherapy at interim analysis. Here, we report the results of the final survival analysis. Methods: A total of 636 patients with treatment-naïve, locally advanced or metastatic nonsquamous non-small cell lung cancer (nsq-NSCLC) without epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK)/ROS proto-oncogene 1 receptor tyrosine kinase (ROS1) genetic alterations were randomized 1:1:1 to receive serplulimab plus HLX04 and chemotherapy (group A), serplulimab plus HLX04 placebo and chemotherapy (group B), or double placebo plus chemotherapy (group C). Patients and the investigators were blinded to the group assignments. The primary endpoint was blinded independent central review-assessed PFS. Overall survival (OS) was the key secondary endpoint. Results: At the final analysis, median OS was 23.7 (95% confidence interval [CI] 20.5 to 27.5) months, 26.8 (95% CI 21.2 to 30.9) months, and 20.3 (95% CI 16.2 to 24.6) months in groups A (n = 212), B (n = 214), and C (n = 210), respectively. A significant reduction in risk of death for group B compared to group C was observed (hazard ratio [HR] = 0.66, 95% CI 0.52 to 0.83; P < 0.001). A total of 79 (37.6%) patients in group C had crossed over to serplulimab plus HLX04 treatment. Median OS in group C adjusted by the 2-stage model was 14.2 months (95% CI 11.9 to 17.0), corresponding to an adjusted HR of 0.53 (95% CI 0.42 to 0.68; P < 0.001) for group B versus group C. Using the rank-preserving structural failure time model, the adjusted median OS in group C was 17.9 months (95% CI 14.2 to 20.3), with a corresponding adjusted HR of 0.65 (95% CI 0.51 to 0.83; P < 0.001). No statistical difference in median OS for group A compared to group B (HR = 1.12, 95% CI 0.88 to 1.42; P = 0.363) was found. Conclusions: Serplulimab plus chemotherapy significantly prolonged OS and maintained PFS benefit compared to chemotherapy; however, the addition of bevacizumab biosimilar HLX04 did not yield further improvement for the first-line treatment of nsq-NSCLC without EGFR or ALK/ROS1 genetic alterations. Trial registration: This trial was registered at ClinicalTrials.gov (NCT03952403, date of registration: 2019 May 14).

KM 提取结果

2 个 Figure · 2 个 KM 面板

进入结果中心
KM Figure1 个面板

Fig. 2.

Fig. 2. Kaplan–Meier survival curve and subgroup analysis of BICR-assessed progression-free survival, showing the progression-free survival benefits with serplulimab plus chemotherapy compared to chemotherapy alone in the intent-to-treat population and across subgroups. (A) In the ITT population. The median PFS was 12.0 (95% CI 8.7 to 13.9) months in group A, 11.0 (95% CI 8.4 to 12.7) months in group B, and 5.7 (95% CI 4.9 to 6.9) in group C. Serplulimab plus chemotherapy significantly improved PFS compared with chemotherapy alone with an HR of 0.54 (95% CI 0.43 to 0.68; P < 0.001). The addition of HLX04 did not translate to an improvement in PFS compared with serplulimab plus chemotherapy (HR = 1.02, 95% CI 0.80 to 1.28; P = 0.896). (B) Exploratory subgroup analysis of PFS in group B vs. group C, suggesting a PFS benefit with serplulimab plus chemotherapy over chemotherapy alone across the various patient subgroups. (C) Exploratory subgroup analysis of PFS in group A vs. group B, implying a lack of PFS benefit with HLX04 and serplulimab plus chemotherapy over serplulimab plus chemotherapy across the various patient subgroups. Group A, serplulimab plus HLX04 and chemotherapy; Group B, serplulimab plus HLX04 placebo and chemotherapy; Group C, serplulimab placebo plus HLX04 placebo and chemotherapy. Abbreviations: BICR, blinded independent central review; CI, confidence interval; CPS, combined positive score; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; ITT, intent-to-treat; NE, not evaluable; NR, not reached; PD-L1, programmed cell death ligand 1; PFS, progression-free survival; TPS, tumor proportion score.

A

progression-free survival

Fig. 2. · Panel A

failed 待 EXE 对齐 预期 3 条 已提取 0 条

Panel A 是同一 Fig. 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 3 条,实际恢复 0 条曲线 1:off origin start曲线 1:extreme upward reversal曲线 2:off origin start
No curves extracted
查看结果
KM Figure1 个面板

Fig. 3.

Fig. 3. Kaplan–Meier survival curve and subgroup analysis of overall survival, showing the overall survival benefits with serplulimab plus chemotherapy compared to chemotherapy alone in the intent-to-treat population and across subgroups. (A) In the ITT population. The median OS was 23.7 (95% CI 20.5 to 27.5) months in group A, 26.8 (95% CI 21.2 to 30.9) months in group B, and 20.3 (95% CI 16.2 to 24.6) in group C. Serplulimab plus chemotherapy significantly improved OS compared with chemotherapy alone with an HR of 0.66 (95% CI 0.52 to 0.83; P < 0.001). The addition of HLX04 did not translate to an OS benefit compared with serplulimab plus chemotherapy (HR = 1.12, 95% CI 0.88 to 1.42; P = 0.363). (B) Exploratory subgroup analysis of OS in group B vs. group C, suggesting an OS benefit with serplulimab plus chemotherapy over chemotherapy alone across the various patient subgroups. (C) Exploratory subgroup analysis of OS in group A vs. group B, implying a lack of OS benefit with HLX04 and serplulimab plus chemotherapy over serplulimab plus chemotherapy across the various patient subgroups. Group A, serplulimab plus HLX04 and chemotherapy; Group B, serplulimab plus HLX04 placebo and chemotherapy; Group C, serplulimab placebo plus HLX04 placebo and chemotherapy. Abbreviations: CI, confidence interval; CPS, combined positive score; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; ITT, intent-to-treat; NE, not evaluable; NR, not reached; OS, overall survival; PD-L1, programmed cell death ligand 1; TPS, tumor proportion score.

A

Overall survival

Fig. 3. · Panel A

complete 待 EXE 对齐 预期 3 条 已提取 3 条

Panel A 是同一 Fig. 3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1.Fig. 1. Study profile. a Two screened patients had EGFR sensitizing mutation or ALK/ROS1 rearrangements and known or documented active central nervous system metastases and/or carcinomatous meningitis. b Included any eligibility criteria that led to failure for enrolment in 2% or less of the screened patients. c Defined as patients who ended the treatment after progressive disease as confirmed by the BICR, died, or completed the 2-year treatment (35 dosing cycles) and would not continue to receive the investigational product as evaluated by the investigator. d Assessed by the investigator. e Patients who withdrew informed consent did not undergo subsequent survival follow-up. f One patient each in group A and group C did not receive any study treatment and were therefore excluded from safety analyses. Between 2019 November 25 and 2022 June 15, a total of 1,538 patients were screened, of whom 636 were randomized. The ITT population consisted of all randomized patients ( n = 636), with 212 in group A, 214 in group B, and 210 in group C; the PPS consisted of all randomized subjects who have received at least one posttreatment tumor assessment without any major protocol deviation that can significantly affect the primary efficacy ( n = 605), with 202 in group A, 208 in group B, and 195 in group C; the SS consisted of all subjects who have received at least one dose of study treatment ( n = 634), with 211 in group A, 214 in group B, and 209 in group C. Abbreviations: AE, adverse event; ALK , anaplastic lymphoma kinase; BICR, blinded independent central review; EGFR , epidermal growth factor receptor; ITT, intent-to-treat; PPS, per-protocol set; ROS1 , ROS proto-oncogene 1 receptor tyrosine kinase; SS, safety set.
非 KM Figure